Discovery Biology Therapeutic Optimization Intern (PhD) jobs in United States
info-icon
This job has closed.
company-logo

AstraZeneca · 1 week ago

Discovery Biology Therapeutic Optimization Intern (PhD)

AstraZeneca is seeking PhD students for a 10-week internship role at their Alexion: AstraZeneca Rare Disease site in New Haven, CT. The role involves developing immunogenicity assays and benchmarking immunogenicity metrics for biologics.

BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
check
Comp. & Benefits
badNo H1Bnote

Responsibilities

Develop immunogenicity Assays for T cell activation
Benchmark immunogenicity metrics of in vitro, in silico, and clinical data
Develop a risk assessment decision tree for discovery biologics for immunogenicity risk assessment

Qualification

ImmunologyCell BiologyBiochemistryImmunofluorescence AssaysMammalian Tissue CulturePublic SpeakingPresentation Design

Required

PhD students studying immunology, cell biology, biophysics, biochemistry, molecular biology, or a related discipline
Candidates must have an expected graduation date after August 2026
At least 2 years of experience in a research lab is required
Experience with immunofluorescence assays is required
The ability to keep high levels of housekeeping, safety, and environmental standards in the laboratory is required
US Work Authorization is required at time of application
Ability to report onsite to our New Haven, CT 4-5 days per week. This role will not provide relocation assistance

Preferred

Experience in mammalian tissue culture is preferred
Completed coursework in immunology is preferred
Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design

Company

AstraZeneca

company-logo
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.

Funding

Current Stage
Public Company
Total Funding
$5.26B
2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B

Leadership Team

leader-logo
Pascal Soriot
Executive Director and Chief Executive Officer
leader-logo
Aradhana Sarin
Group CFO and Executive Director
linkedin
Company data provided by crunchbase